Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Privia Health Group , Inc. (NASDAQ:PRVA), a healthcare company currently trading at a high earnings multiple according to InvestingPro data, saw its Executive Vice President and Chief Financial Officer David Mountcastle recently execute sales of company stock totaling $141,658. The company, which maintains strong financial health with more cash than debt on its balance sheet, has seen its shares rise over 27% in the past six months. According to a recent SEC filing, Mountcastle sold 2,979 shares at $24.53 per share on March 10 and 2,872 shares at $23.88 per share on March 11. These transactions were part of a nondiscretionary sale to cover tax obligations related to vesting restricted stock units. Following these sales, Mountcastle holds 185,306 shares directly and an additional 8,695 shares indirectly through his spouse. For deeper insights into insider trading patterns and 10+ additional exclusive ProTips, explore InvestingPro’s comprehensive analysis tools.
In other recent news, Privia Health Group has made significant changes to the compensation package for one of its top executives, Parth Mehrotra. Starting March 24, 2025, Mehrotra will receive an annual base salary of $650,000, with the potential to earn a performance bonus of up to 125% of his base salary. Additionally, he is eligible for an annual long-term incentive award valued at $8 million. Analysts have also been active in updating their outlooks for Privia Health. Jefferies raised its price target for the company to $29, citing strong cash generation and minimal regulatory exposure. Canaccord Genuity increased its target to $30, highlighting Privia’s consistent performance and prudent business strategy. JMP Securities adjusted its target to $29, noting the company’s solid guidance for 2025, including projected Practice Collections of $3.15 billion to $3.25 billion. Piper Sandler provided the most optimistic outlook with a price target of $40, praising Privia Health’s strategic approach to value-based care and its potential for profitable growth. These developments reflect the company’s robust position in the healthcare market and its effective management strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.